Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects

J Endocrinol Invest. 1984 Jun;7(3):211-4. doi: 10.1007/BF03348425.

Abstract

The effect of a recently described, potent opioid peptide, dermorphin (DER), on TSH secretion in euthyroid subjects has been studied. DER infused at a rate of 5.5 micrograms/Kg/min for 30 min induced a significant increase in serum TSH concentration at 60, 90, and 120 min after the infusion was begun. Treatment with naloxone administered 30 min before the DER infusion with a bolus dose of 4 mg, followed by a constant infusion of 1 microgram/Kg/min for 150 min, prevented the rise in serum TSH. Naloxone administered alone did not induce any change in TSH concentration. The present findings suggest that DER has a stimulatory effect on TSH secretion, probably mediated by opioid receptors. These results, however, do not solve the question as to whether opioids have a physiological role in the control of pituitary TSH secretion.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Humans
  • Male
  • Naloxone / pharmacology
  • Narcotics / pharmacology
  • Oligopeptides / pharmacology*
  • Opioid Peptides
  • Secretory Rate / drug effects
  • Thyrotropin / blood
  • Thyrotropin / metabolism*
  • Time Factors

Substances

  • Narcotics
  • Oligopeptides
  • Opioid Peptides
  • dermorphin
  • Naloxone
  • Thyrotropin